|6 Months Ended|
May 31, 2017
|SEGMENT INFORMATION [Text Block]||
NOTE 3 - SEGMENT INFORMATION
The Chief Executive Officer ("CEO") is the Company’s chief operating decision-maker ("CODM").
Based on the Company's organizational structure, its business activities and information reviewed by the CODM for the purposes of allocating resources and assessing performance, management has determined that there are two operating segments.
The CDMO activity is comprised of a specialization in cell therapy development for advanced therapeutic products and providing two types of services to its customers: (i) process and assay development services and (ii) cGMP contract manufacturing services. The CDMO activities include the operations of MaSTherCell.
The Cellular Therapy Business (“CTB”) activity is based on the technology licensed by the Israeli Subsidiary, that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into “pancreatic beta cell-like” insulin producing cells for patients with Type 1 Diabetes.
The Company assesses the performance based on a measure of "Adjusted EBIT" (earnings before financial expenses and tax, and excluding share-based compensation expenses and non-recurring income or expenses). The measure of assets has not been disclosed for each segment.
Segment data for the six months ended May 31, 2017 is as follows:
* Excluding $1,624 thousand stock based compensation included in financial expenses.
Segment data for the six months ended May 31, 2016 is as follows:
Segment data for the three months ended May 31, 2017 is as follows:
* Excluding $1,084 thousand stock based compensation included in financial expenses.
Segment data for the three months ended May 31, 2016 is as follows:
Geographic, Product and Customer Information
Substantially all the Company's revenues and long lived assets are located in Belgium.
Revenues from single customers from the CDMO segment that exceed 10% of total net revenues are:
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
Reference 1: http://www.xbrl.org/2003/role/presentationRef